Axol produces high-quality human cell products and critical reagents such as media and growth supplements. We have a passion for great science, delivering epic support and innovating future products to help our customers advance faster in their research.
Our expertise includes reprogramming cells to iPSCs and then differentiating to various cell types. We supply differentiated cells derived from healthy donors and patients of specific disease backgrounds. As a service, we also take cells provided by customers (primary or iPSC) and then do the reprogramming (when necessary) and differentiation. Clearly, by offloading the burden of generating cells, your time is freed up to focus on the research. Axol holds the necessary licenses that are required to do iPSC work.
The package wouldn't be complete without optimized media, coating solutions and other reagents. Our in-house R&D team works hard to improve on existing media and reagents as well as innovate new products for human cell culture. We also supply a growing range of human primary cells; making Axol your first port of call for your human cell culture needs.
PsychoGenics is a leader in in vivo drug discovery whose capabilities include behavioral testing, electrophysiology, EEG, histology, and microdialysis. Complementing its extensive capabilities are a variety of mouse models, including transgenic models, in areas such as Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and psychosis/schizophrenia. PsychoGenics has also pioneered the translation of rodent behavioral responses into robust, high-throughput, high content phenotyping and its drug discovery platforms, SmartCube®, NeuroCube®and PhenoCube® have led to shared risk partnerships with companies such as Sunovion and Roche and has resulted in the discovery of several novel compounds in clinical trials or advanced preclinical development.
Cellectricon is a collaborative services provider dedicated to advance drug discovery and research in the areas of chronic pain and neurodegenerative disease. We are a team of highly experienced neurobiologists, stem cell researchers and engineers, with a proven track record of developing innovative in-vitro assays of enhanced translational value. With our unique drug discovery platform, we provide valuable decision-making information obtained from complex cell-based disease models. We always aim for long-term partnerships with our Clients, based on mutual trust and commitment.
QPS Neuropharmacology is a preclinical full-service contract research organization (CRO) focusing on CNS diseases, Orphan diseases and mental disorders.
The availability of highly predictive disease models and unparalleled experience with studies performed for biopharmaceutical companies of all sizes makes QPS the first choice for most needs in CNS drug development.
Validated transgenic and non-transgenic in vitro and in vivo models cover most targets of Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Huntington’s Disease (HD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Niemann-Pick Disease, Autism Spectrum Disorder (ASD), Schizophrenia, Lewy Body Dementia (LBD) and other neurodegenerative diseases.
NeuroProof as a contract research organization is a global leader and preferred partner in the field of microelectrode array (MEA)-based phenotypic screening of primary cultures or hiPSC derived neuronal cultures. NeuroProof offers screening services and state-of-the-art mathematical expertise for the artificial intelligence-based analysis of test agents on neuronal network activity. The services comprise the growing of neuronal cultures on MEA chips, medium-throughput screening of test agents, high-quality recording of spontaneous and compound-induced network activity, state-of-the-art mathematical analyses, and sophisticated pattern recognition methods. NeuroProof is your partner for developing new in vitro disease models with its functional phenotypic screening technology.
The unique platform is well suited to identify and characterize effects of test agents on neuronal network activity, brain cell functioning, synaptogenesis and behavioral connectivity.
Neuro-Sys is a pharmacology company that relies on the expertise and experience of pharmacists and pharmacologists specialized in the R&D of molecules used to treat neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. It is specialized in in vitro screening of neuro active molecules and mode of action research.It also accompanies and advises her clients in the drug development from preclinical trials to the clinical phase.
Biorasi provides solutions that aren’t just valid today – they are built to move sponsor trials forward no matter what the future issues may be. We prepare for what comes next, whether it be regulation, technology, trial design, challenges, or complexities. We anticipate the roadblocks and can promise that we will move your trials forward over any obstacle through our partnership. Biorasi has architected a set of systems, methodologies, and processes that allow us to be attentive, responsive, and results-oriented that outperform CRO Industry Standards.
Spun out of GlaxoSmithKline in 2010, Transpharmation was created to be a neuroscience CRO with a difference; cross-therapeutic area expertise in translational pharmacology from bench to bedside. Transpharmation is led by a team with decades of drug discovery and business expertise. We’ve successfully built client and science-focused relationships across our extensive network in the pharmaceutical and biotechnology sectors. Our clients are our partners, we work hard to create breakthrough results for them.
The Science Behind combines pharmacology and neuroscience expertise to provide a service that offers an array of electro-diagnostic markers to assess human brain excitability and functionality in health and disease. For those looking to evaluate in-vivo markets for pharmacological activity and/or in-vivo markers for specific biological processes we can support trials with protocol design, delivery, data analysis and reporting.